Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBCBS Iowa Pasatru Prior Auth Policy | OpenPayer
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - IowaPolicy 05.06.38

    Pasatru (garetosmab-grts) Coverage for Fibrodysplasia Ossificans Progressiva

    Customize your policy alerts

    Sign up for Blue Cross Blue Shield - Iowa Policy 05.06.38 alerts

    Get alerted when Policy 05.06.38 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and medical-necessity coverage for Pasatru (garetosmab-grts) in adults with fibrodysplasia ossificans progressiva, subject to coverage criteria, documentation requirements, and dosing limits.

    Policy Summary
    PayerBlue Cross Blue Shield - Iowa
    PolicyPasatru (garetosmab-grts) Coverage for Fibrodysplasia Ossificans Progressiva
    Policy CodePolicy 05.06.38
    Change TypeNo material change
    Effective DateOct 25, 2026
    Last ReviewOct 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with diagnosis confirmation and active-disease documentation for initial requests, or documentation of treatment benefit for continuation requests.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12 monthsAuthorization period
    ≤ 19

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Initial CAJIS limit
    10 mg/kg q4wDosing
    4 vials/28 daysQuantity limit
    Adults with FOPCovered population

    Coverage Criteria

    Initial Therapy

    Authorization for 12 months may be granted for initial treatment when all of the following criteria are met:

    Initial therapy requirements

    • Confirmed diagnosis: Member has a confirmed diagnosis of fibrodysplasia ossificans progressiva (FOP) by genetic testing indicating a pathogenic activin receptor type 1 (ACVR1) FOP-causing variant, such as R206H.
    • Characteristic FOP signs and symptoms: Member has congenital malformation of the great toe and episodic soft-tissue swelling and/or ectopic ossification in ligament or muscle tissue.

      Both manifestations are required.

    • Active disease: Member has evidence of active disease, such as FOP flare-ups, worsening joint function, or radiographic progression of heterotopic ossification lesions.Within the past 12 months
    • Baseline disease severity: Member has a Cumulative Analog Joint Involvement Scale (CAJIS) score no greater than 19 at baseline.CAJIS ≤ 19
    • No active or recent malignancy: Member has no active or recent malignancy.
    • Controlled comorbid illness: Member has no significant uncontrolled comorbid illness, such as cardiac, neurologic, or rheumatologic disease.
    • Pregnancy testing when applicable: Females of reproductive potential have a negative pregnancy test.Negative pregnancy test
    • Reproductive status: Member is not currently breastfeeding, pregnant, or planning pregnancy.
    • No palovarotene combination: The requested medication will not be used in combination with palovarotene (Sohonos).

    Continuation Therapy

    Authorization for 12 months may be granted for continued treatment when all of the following criteria are met:

    Continuation therapy requirements

    • Benefit from therapy: Member is experiencing benefit from therapy, evidenced by disease improvement or disease stability, such as stability or reduction in the volume of new heterotopic ossification or reduced frequency or severity of clinician-assessed flare-ups.Disease improvement or stability
    • No contraindicating serious adverse event: Member has had no serious adverse event that would contraindicate continued therapy, such as serious uncontrolled epistaxis or serious skin/soft-tissue infection.
    • Reproductive status: Member is not currently breastfeeding, pregnant, or planning pregnancy.

    Pasatru must not be used in combination with palovarotene (Sohonos) for either initial or continuation therapy.

    For initial therapy, the member must have no active or recent malignancy and no significant uncontrolled comorbid illness, including cardiac, neurologic, or rheumatologic disease.

    For continuation therapy, the member must have had no serious adverse event that would contraindicate continued treatment, including serious uncontrolled epistaxis or a serious skin or soft-tissue infection.

    Pasatru is not medically necessary for members who do not meet the stated coverage criteria.

    Coding and Clinical Thresholds

    Procedures and Billing CodesHCPCS
    J3590Unclassified biologics
    C9399Unclassified drugs or biologics (for hospital outpatient department claims only)
    Baseline Disease Severity
    ScaleCumulative Analog Joint Involvement Scale (CAJIS)
    Baseline thresholdCAJIS score less than or equal to 19 at baseline
    Applies toInitial authorization for adult members with fibrodysplasia ossificans progressiva

    Provider Requirements and Decision Risks

    Prior Authorization

    Prior Authorization and Qualified Prescriber

    Prior authorization is required for Pasatru. Authorization may be granted for 12 months when the applicable initial or continuation coverage criteria are met. The medication must be prescribed by, or prescribed in consultation with, a physician experienced in treating fibrodysplasia ossificans progressiva (FOP), such as an endocrinologist, orthopedist, rheumatologist, or neurologist.

    • Apply the initial-request criteria for new therapy and the continuation criteria for reauthorization.
    • The qualified prescriber or consultant should have experience treating FOP.
    Documentation Required

    Initial Request Documentation

    Initial requests must include documentation establishing the diagnosis and clinical need for Pasatru.

    • Genetic test results confirming FOP with a pathogenic ACVR1 variant, such as R206H.

    Clinical Background

    Fibrodysplasia ossificans progressiva (FOP) is characterized by congenital malformation of the great toe and episodic soft-tissue swelling and/or ectopic ossification in ligament or muscle tissue. Pasatru is used in adults with FOP to reduce formation of new heterotopic ossification lesions and clinician-assessed flare-ups.

    Initial Therapy Criteria

    Initial Therapy

    Authorization of 12 months may be granted for initial treatment when all initial approval criteria are met:

    Initial therapy

    • Confirmed diagnosis: Member has a confirmed diagnosis of fibrodysplasia ossificans progressiva (FOP) by genetic testing indicating a pathogenic activin receptor type 1 (ACVR1) FOP-causing variant, such as R206H.
    • Characteristic FOP signs and symptoms: Member has congenital malformation of the great toe and episodic soft-tissue swelling and/or ectopic ossification in ligament or muscle tissue.

      Both manifestations are required.

    • Active disease: Member has evidence of active disease, such as FOP flare-ups, worsening joint function, or radiographic progression of heterotopic ossification lesions.

    Continuation Therapy Criteria

    Continuation Therapy

    Authorization for 12 months may be granted for continued treatment when all continuation criteria are met:

    Continuation therapy

    • Benefit from therapy: Member is experiencing benefit from therapy, evidenced by disease improvement or disease stability, such as stability or reduction in the volume of new heterotopic ossification or reduced frequency or severity of clinician-assessed flare-ups.Disease improvement or stability
    • No contraindicating serious adverse event: Member has had no serious adverse event that would contraindicate continued therapy, such as serious uncontrolled epistaxis or serious skin/soft-tissue infection.
    • Reproductive status: Member is not currently breastfeeding, pregnant, or planning pregnancy.

    Quantity Limits

    Quantity Limits
    ProductPasatru (garetosmab-grts) 300 mg/5 mL single-dose vial
    Standard quantity limit4 vials per 28 days
    FDA-recommended dosing10 mg/kg by intravenous infusion once every 4 weeks
    Dose adjustment if not toleratedThe dosage may be decreased to 3 mg/kg once every 4 weeks
    Policy Summary
    PayerBlue Cross Blue Shield - Iowa
    PolicyPasatru (garetosmab-grts) Coverage for Fibrodysplasia Ossificans Progressiva
    Policy CodePolicy 05.06.38
    Change TypeNo material change
    Effective DateOct 25, 2026
    Last ReviewOct 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with diagnosis confirmation and active-disease documentation for initial requests, or documentation of treatment benefit for continuation requests.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Clinical ThresholdsProvider Requirements and Decision RisksClinical BackgroundInitial Therapy CriteriaContinuation Therapy CriteriaQuantity Limits
    No palovarotene combination: The requested medication will not be used in combination with palovarotene (Sohonos).
  1. Chart notes or medical-record documentation of FOP signs and symptoms: congenital malformation of the great toe and episodic soft-tissue swelling and/or ectopic ossification in ligament or muscle tissue.
  2. Documentation of active disease within the past 12 months, such as FOP flare-ups, worsening joint function, or radiographic progression of heterotopic ossification lesions.
  3. Documentation Required

    Continuation Request Documentation

    Continuation requests must document that the member is benefiting from therapy before reauthorization is approved.

    • Submit chart notes or medical-record documentation supporting benefit from therapy.
    • Evidence may include disease improvement or stability, such as stable or reduced volume of new heterotopic ossification or reduced frequency or severity of clinician-assessed flare-ups.
    Denial Risk

    Failure to Meet Coverage Criteria

    Pasatru is not medically necessary when the member does not meet the applicable coverage criteria.

    • Requests that fail the initial or continuation criteria may be denied.
    Denial Risk

    Excluded Combination or Safety Concerns

    Do not approve Pasatru when combination use or applicable safety criteria create a contraindication or exclusion.

    • The requested medication must not be used in combination with palovarotene (Sohonos).
    • For initial requests, the member must have no active or recent malignancy and no significant uncontrolled comorbid illness, such as cardiac, neurologic, or rheumatologic disease.
    • Females of reproductive potential must have a negative pregnancy test; the member must not be pregnant, breastfeeding, or planning pregnancy.
    • For continuation requests, there must be no serious adverse event contraindicating continued therapy, such as serious uncontrolled epistaxis or serious skin/soft-tissue infection.
    • The member must not be pregnant, breastfeeding, or planning pregnancy for continuation therapy as well.
    Within the past 12 months
  4. Baseline disease severity: Member has a Cumulative Analog Joint Involvement Scale (CAJIS) score no greater than 19 at baseline.CAJIS ≤ 19
  5. No active or recent malignancy: Member has no active or recent malignancy.
  6. Controlled comorbid illness: Member has no significant uncontrolled comorbid illness, such as cardiac, neurologic, or rheumatologic disease.
  7. Pregnancy testing when applicable: Females of reproductive potential have a negative pregnancy test.Negative pregnancy test
  8. Reproductive status: Member is not currently breastfeeding, pregnant, or planning pregnancy.
  9. No palovarotene combination: The requested medication will not be used in combination with palovarotene (Sohonos).
  10. No palovarotene combination: The requested medication will not be used in combination with palovarotene (Sohonos).